{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:02:16Z","timestamp":1780408936117,"version":"3.54.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hepatitis C virus (HCV) guidelines recommend direct-acting antiviral (DAA) rescue regimens in cases of treatment failure, and first-line regimens for reinfection. In patients with barriers to follow-up after treatment, it is difficult to determine if HCV viremia represents failure or reinfection. Patients are often retreated with rescue regimens despite higher costs. We compared the outcome of first-line vs rescue therapy in DAA experienced patients whose prior outcome was indeterminate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study included DAA experienced adults undergoing retreatment at a hospital in Massachusetts between January 2016 and May 2022. We used descriptive statistics to characterize the population. For patients with an indeterminate prior HCV treatment outcome, we compared the groups\u2019 characteristics and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 112 patients. The mean age was 52 years (SD: 12.2), 80.4% were male, and 42.9% were White. Nearly 1 in 4 (25%) reported active substance use. Outcomes of prior DAA treatment included sustained virologic response at 12 weeks in 39.3% (n = 44) and treatment failure in 27.7% (n = 31). The prior treatment outcome was indeterminate in 33% (n = 37). We compared the outcomes of patients with an indeterminate treatment outcome retreated with first-line vs rescue therapy. Sustained virologic response at 12 weeks (66.7 vs 52.7%), treatment failure (0% vs 10.5%), and indeterminate outcome (33.3% vs 36.8%) were similar between the groups (P = .502).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Outcomes with first-line DAAs were comparable to rescue medications for retreatment of patients with DAA experience and an indeterminate prior treatment outcome. Our findings can help decrease treatment-level barriers for HCV treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae704","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T21:58:22Z","timestamp":1732744702000},"source":"Crossref","is-referenced-by-count":2,"title":["Characteristics and Outcomes of Direct-Acting Antiviral Experienced Patients with Hepatitis C Undergoing Retreatment at an Essential Hospital in the United States"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-1258","authenticated-orcid":false,"given":"Alejandro","family":"De La Hoz","sequence":"first","affiliation":[{"name":"Department of Medicine, Boston Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"Chobanian and Avedisian School of Medicine, Boston University , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Pooja","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Boston Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kancharla","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Boston Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1798-9663","authenticated-orcid":false,"given":"Elissa M","family":"Schechter-Perkins","sequence":"additional","affiliation":[{"name":"Chobanian and Avedisian School of Medicine, Boston University , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Emergency Medicine, Boston Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1769-6094","authenticated-orcid":false,"given":"Glorimar","family":"Ruiz-Mercado","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7111-0344","authenticated-orcid":false,"given":"Marielle","family":"Baldwin","sequence":"additional","affiliation":[{"name":"Chobanian and Avedisian School of Medicine, Boston University , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Family Medicine, Boston Medical Center , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nunes","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"Chobanian and Avedisian School of Medicine, Boston University , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Medicine, Boston Medical Center , Boston, Massachusetts ,","place":["USA"]},{"name":"Chobanian and Avedisian School of Medicine, Boston University , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2024121912143280600_ofae704-B1","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"2024121912143280600_ofae704-B2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"2024121912143280600_ofae704-B3","volume-title":"Global health sector strategy on viral hepatitis 2016\u20132021","author":"World Health Organization","year":"2016"},{"key":"2024121912143280600_ofae704-B4","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Heal"},{"key":"2024121912143280600_ofae704-B5","doi-asserted-by":"crossref","first-page":"551500","DOI":"10.3389\/fphar.2020.551500","article-title":"Predicting treatment failure for initiators of hepatitis C virus treatment in the era of direct-acting antiviral therapy","volume":"11:","author":"Nabulsi","year":"2020","journal-title":"Front Pharmacol"},{"key":"2024121912143280600_ofae704-B6","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/cid\/ciz985","article-title":"Moving towards hepatitis C microelimination among people living with human immunodeficiency virus in Australia: the CEASE study","volume":"71","author":"Martinello","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024121912143280600_ofae704-B7","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/cid\/ciaa645","article-title":"Incidence of HCV reinfection among HIV-positive MSM and its association with sexual risk behavior: a longitudinal analysis","volume":"73","author":"Newsum","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024121912143280600_ofae704-B8","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"2024121912143280600_ofae704-B9","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C guidance 2023 update: aASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024121912143280600_ofae704-B10","doi-asserted-by":"crossref","first-page":"e0218388","DOI":"10.1371\/journal.pone.0218388","article-title":"HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center","volume":"14","author":"Calner","year":"2019","journal-title":"PLoS One"},{"key":"2024121912143280600_ofae704-B11","doi-asserted-by":"crossref","first-page":"ofac445","DOI":"10.1093\/ofid\/ofac445","article-title":"The hepatitis C care cascade during the direct-acting antiviral era in a United States commercially insured population","volume":"9","author":"Ferrante","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024121912143280600_ofae704-B12","doi-asserted-by":"crossref","first-page":"103422","DOI":"10.1016\/j.drugpo.2021.103422","article-title":"Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort","volume":"96","author":"Carson","year":"2021","journal-title":"Int J Drug Policy"},{"key":"2024121912143280600_ofae704-B13","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1002\/jmv.26971","article-title":"Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C","volume":"93","author":"Elhence","year":"2021","journal-title":"J Med Virol"},{"key":"2024121912143280600_ofae704-B14","doi-asserted-by":"crossref","first-page":"4029541","DOI":"10.1155\/2019\/4029541","article-title":"Real world experience of chronic hepatitis C retreatment with genotype specific regimens in nonresponders to previous interferon-free therapy","volume":"2019","author":"Zar\u0229bska-Michaluk","year":"2019;","journal-title":"Can J Gastroenterol Hepatol"},{"key":"2024121912143280600_ofae704-B15","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00535-019-01575-9","article-title":"Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1\/2\/3 infections","volume":"54","author":"Sezaki","year":"2019","journal-title":"J Gastroenterol"},{"key":"2024121912143280600_ofae704-B16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/civ874","article-title":"Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens","volume":"62","author":"Wilson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024121912143280600_ofae704-B17","first-page":"16400","article-title":"Effectiveness of pangenotypic retreatment of chronic hepatitis C after prior failure of pangenotypic therapies","volume":"133","author":"Jaroszewicz","year":"2023","journal-title":"Pol Arch Intern Med"},{"key":"2024121912143280600_ofae704-B18","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jceh.2023.03.007","article-title":"Hepatitis C retreatment with first-line direct acting antiviral drugs","volume":"13","author":"Goel","year":"2023","journal-title":"J Clin Exp Hepatol"},{"key":"2024121912143280600_ofae704-B19","doi-asserted-by":"crossref","first-page":"102388","DOI":"10.1016\/j.bjid.2022.102388","article-title":"National Brazilian survey on the outcomes of hepatitis C retreatment in patients non-responders to direct antiviral agents","volume":"26","author":"Ferraz","year":"2022","journal-title":"Braz J Infect Dis"},{"key":"2024121912143280600_ofae704-B20","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.29671","article-title":"Glecaprevir\/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure","volume":"67","author":"Poordad","year":"2018","journal-title":"Hepatology"},{"key":"2024121912143280600_ofae704-B21","doi-asserted-by":"crossref","first-page":"E799","DOI":"10.1093\/cid\/ciaa1510","article-title":"Salvage therapy with sofosbuvir\/velpatasvir\/voxilaprevir in DAA-experienced patients: results from a prospective Canadian registry","volume":"72","author":"Onofrio","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024121912143280600_ofae704-B22","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis C patients with previous DAA failure","volume":"71","author":"Degasperi","year":"2019","journal-title":"J Hepatol"},{"key":"2024121912143280600_ofae704-B23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s12072-022-10475-9","article-title":"Sofosbuvir\/velpatasvir\/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan","volume":"17","author":"Liu","year":"2023","journal-title":"Hepatol Int"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae704\/60836957\/ofae704.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/12\/ofae704\/60836957\/ofae704.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/12\/ofae704\/60836957\/ofae704.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:14:57Z","timestamp":1734610497000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae704\/7909884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae704","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,11,27]]},"article-number":"ofae704"}}